Deviations from normal cell death programs tend to promote cell survival and are frequently associated with cancer. Many anti-cancer medicines aim to selectively induce cell death in tumor cells, but highly validated non-invasive biomarkers to assess such molecular events are lacking. This study reports a novel positron emission tomography (PET) molecular imaging agent that allows non-invasive, targeted detection of caspase activation and tumor cell death following effective drug treatment. The probe evaluated here was studied within the context of molecularly targeted therapy, but could be equivalently effective to evaluate response to conventional therapeutics and thus used to predict individualized responses in patients and accelerate the development of improved cancer therapies.
Introduction
Cell death proceeds through multiple, mechanistically distinct processes that include necrosis, autophagy, mitotic catastrophe, and apoptosis (1, 2) . Apoptosis, or programmed cell death, is an orchestrated process that facilitates elimination of unnecessary, damaged, or compromised cells to confer an overall advantage to the host organism. As such, apoptosis is an essential component of embryonic development, tissue homeostasis, and immunological competence. Deviations from normal apoptotic programs are frequently associated with human diseases such as cancer (3) . Since many anti-cancer therapies aim to selectively induce apoptosis in tumor cells (4, 5) , quantitative, non-invasive imaging biomarkers that reflect apoptosis represent promising tools to improve drug discovery and predict early responses in patients (6) (7) (8) (9) (10) .
Clinically robust molecular imaging biomarkers of apoptosis have been sought after for many years, but
none have yet proven optimal. Classically, molecular imaging measures of apoptosis have relied upon labeled forms of the 36 kDa protein Annexin V, which binds to externalized phosphatidylserine on the plasma membrane of cells undergoing apoptosis (7, 11) . Though functionalization of Annexin V for optical (9, 10) , single-photon emission computed tomography (SPECT) (12, 13) , and positron emission tomography (PET) (14, 15) imaging have been reported, imaging probes based on Annexin V generally suffer from limitations that include suboptimal biodistribution and pharmacokinetics, calcium ion-dependency (16) , and a lack of specificity (17) (18) (19) . Another promising approach that capitalizes upon cell membrane alterations associated with apoptosis utilizes a small molecule known as 18 F-ML-10, which has been evaluated in a limited number of patients (20, 21) . The strengths and weaknesses of this approach are under investigation at a number of institutions.
Other intracellular molecular targets within the apoptosis signaling cascade represent opportunities for molecular probe development. For example, as regulators of extrinsic and intrinsic apoptosis, caspases have been suggested as promising targets for molecular imaging and for drug development (6, 22) . The goal of this study was to explore the utility of a peptide-based pan-caspase inhibitor, the modified tripeptide sequence Val-Ala-Asp(OMe)-fluoromethylketone (VAD-FMK) (23, 24) , to serve as the basis for developing a PET imaging probe for detecting apoptosis. To this end, we report that [ 18 F]4-fluorobenzylcarbonyl-Val-
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Molecular Modeling
Co-crystal structures for the caspase-3 protein with an aza-peptide epoxide inhibitor (PDB ID 2CNN) (25) and a covalently bound β-strand peptidomimetic inhibitor (PDB ID 3KJF) (26) were obtained from the Brookhaven Protein Data Bank and used to evaluate the potential of prosthetically labeled VAD-FMK, and deviations thereof, to be accommodated within the active caspase-3 binding domain. Structural alignment of both caspase-3 inhibitor co-crystal structures was performed using PyMOL (Molecular Graphics System, compared to parent peptide was evaluated as described in supporting information (SI). Lipophilicity measurements (LogP 7.5 ) of peptide derivatives were determined analogously to reported methods (27) and described in supporting information (SI).
Biochemical Caspase-3 Inhibition Assay
Research. Caspase-Glo 3/7 (Promega) was employed as a readout of inhibition where by a caspase-cleavable protected luciferase substrate is directly sensitive to caspase-3/7 activity and quantifiable by bioluminescence (28) . Caspase inhibitor dissolved in DMSO (0, 0.1, 1, 10, 100, 1000, or 10000 nM) was combined with recombinant human caspase-3 enzyme (C1224-10UG, Sigma) (100 nM) in 1X phosphate buffered saline (PBS) in microcentrifuge tubes, vortexed, and incubated at 37°C for 30 min. After incubation, Caspase-Glo 3/7 reagent (Promega) was added in accordance with the manufacturer's instructions. Solutions were vortexed, incubated for an additional 30 min, and dispensed into opaque wall/bottom 384-well plates (BD Biosciences) for measurement of caspase activity. Sample luminescence was measured using a Synergy 4 plate reader (BioTek).
Cellular Caspase Inhibition Assay
DiFi cells were propagated in Dulbecco's Modified Eagle's Medium (DMEM, Mediatech) and supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1 mg/mL gentamycin sulfate (Gibco) in a 95% humidity, 5% CO 2 , 37°C atmosphere. Cells were seeded as sub-confluent monolayer cultures at a density of 1 x 10 4 per well into 96-well, black wall/bottom plates (BD Biosciences) and allowed to adhere for 24 h at 37°C. For evaluation of caspase-3/7 inhibition concomitant with drug exposure, DiFi cells were incubated with cetuximab (0.5 µg/mL) for 24 h, based on our experience from previous work (9) . Cell media was then replaced with 1X PBS containing inhibitor (0, 10, 100, 1000, 10000 nM) and incubated at 37°C for 30 min. Inhibition was assessed using Caspase-Glo 3/7 reagent in accordance with the manufacturer's instructions. Luminescence was quantified using a Synergy 4 plate reader.
Radiotracer Preparation
Detailed chemical and radiochemical methods and characterization can be found in supporting information (SI 
Animal Model
Research. Studies involving animals were conducted in accordance with federal and institutional guidelines.
Biodistribution studies were performed using male C57BL/6 mice. A detailed description of in vitro drug response studies that support the subsequently described animal models and drug therapies is provided in the supporting information (SI). 
In Vivo PET Imaging and Analysis
Imaging acquisition and processing was performed analogously to our previously reported methods (32) .
Further details are reported in supporting information (SI).
Immunohistochemistry (IHC)
Tumor tissues were harvested immediately following conclusion of imaging, fixed for 24 h in 5% #9664) was carried out as previously described (9) . Tissues were stained using standard H&E methods and reviewed by an expert gastrointestinal pathologist (M. Kay Washington). Images displayed are representative of three randomly selected high-power fields (40x). Semi-quantitative IHC analysis was performed using the image processing software ImageJ and is described in supporting information (SI).
Statistical Methods
Unless otherwise stated, experimental replicates are reported as the arithmetic mean ± standard deviation. Statistical significance of in vitro and in vivo data sets was evaluated using an unpaired, two-tailed t-test. Differences were assessed within the GraphPad Prism 6.01 software package and considered statistically significant if p < 0.05.
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Results
Caspase-3 Active Site Accommodates N-Terminal Functionalization of VAD-FMK
Imaging labels should impart minimal, if any, effects upon the biological and chemical properties of the parent molecule. Given this, we initially used a molecular modeling approach to explore multiple Nterminally functionalized analogues of VAD-FMK (Fig. 1A) , two of which would result in PET/SPECT imaging probes: FB-VAD-FMK (Fig. 1B) Table   S1 ). The Surflex-Dock scoring term for Polar contacts suggested that the FB-VAD-FMK peptide had greater potential to form hydrogen bonds with active caspase-3 site residues relative to other candidate structures, including the parent peptide, while displaying less internal ligand Strain scores. Of note, IZ-VAD-FMK produced docking scores that reflected a lower-scoring Polar term and demonstrated that more poses buried the larger, lipophilic iodo-moiety toward the protein active site, suggesting greater lipophilicity than FB-VAD-FMK. Though exploratory in nature, these studies suggested both tolerance to functionalization of VAD-FMK at the N-terminus with the FB prosthesis and that the resulting PET imaging probe might possess favorable physical and chemical properties relative to parent peptide and the IZ-labeled form.
Enzyme Selectivity of VAD-FMK Peptide Analogues
From the binding mechanism of VAD-FMK-type peptides (23, 34) , we anticipated that FB-VAD-FMK would exhibit caspase selectivity similar to that of the parent peptide. To explore this, we evaluated the relative affinity of [
19 F]FB-VAD-FMK against activated caspases-3/6/7/8 (Fig. S1) . Addition of the FB- 
prosthesis had little impact on caspase selectivity compared to that of the parent peptide, where both peptides inhibited caspases-3/6/7 with single micro molar potency and caspase-8 with slightly greater potency. Caspase-3 was used in subsequent characterization and validation studies as a representative of other relevant caspases.
Lipophilicity of VAD-FMK Peptide Analogues
To validate the predicted physical properties of the labeled VAD-FMK derivatives, lipophilicity studies were undertaken using [
19 F]FB-VAD-FMK (Fig. S2A) , Z-VAD-FMK, and [ 127 I]IZ-VAD-FMK (Fig. S2B) .
We determined that the FB-modified peptide (logP 7.5 = 1.41) was between 50 -100 times less lipophilic (Fig. 1D, E tissue counting at 60 min post-administration and correlative PET imaging up to 75 min post-administration.
Upon intravenous administration, [
18 F]FB-VAD-FMK was widely distributed throughout a range of normal tissues, with the greatest activity in kidneys and liver after 60 minutes of uptake ( Fig. 2A) (Fig. 2B, C) , agreed with tissue counting measurements and provided evidence of renal and hepatobiliary excretion. This was confirmed by HPLC radiometabolite analysis, using a protocol analogous to that described in supporting information (SI) for radiochemical purity analysis, which revealed largely parent compound, approximately 50% or greater, in bile and urine samples (n = 3) at 60 min post injection.
[ 18 F]FB-VAD-FMK PET Reflects AZD-1152-dependent Caspase-3 Activity in Tumors
In vivo uptake of [ 18 F]FB-VAD-FMK in tumor was evaluated in SW620 and DLD-1 human CRC cell line xenografts given the in vitro data which demonstrated, in concert with polyploidy ( Fig. 3A) , AZD-1152-HQPA concentration-dependent increases in cleaved PARP and cleaved caspase-3 levels (Fig. 3B) .
These results, in addition to previously reported in vivo findings (35) , suggest that quantification of caspase activity may reflect response to Aurora B kinase inhibition in these models. (Fig. 4A-C) , which was in agreement with in vitro studies. Interestingly, [ 18 F]FB-VAD-FMK uptake was absent in areas of central necrosis, as evident from 3D PET images (Fig. 4A) . Interestingly, unlike in vitro studies that illustrated the sensitivity of DLD-1 cells to AZD-1152, probe accumulation was similar between AZD-1152-treated and vehicle-treated DLD-1 xenografts (0.57 ± 0.14 %ID/g and 0.49 ± 0.22 %ID/g respectively, p = 0.510).
In vivo
To validate imaging, xenograft tissues were harvested for histology immediately following imaging. In agreement with [ 18 F]FB-VAD-FMK PET, caspase-3 immunoreactivity appeared modest in both vehicletreated SW620 and DLD-1 xenografts (Fig. 4D) . Furthermore, AZD-1152 treatment led to elevated caspase- 3 immunoreactivity compared to vehicle-treatment in SW620 but not DLD-1 xenografts as verified with semi-quantitative IHC analysis (Fig. S4A) . AZD-1152-treated SW620 xenografts demonstrated evidence of drug exposure given the presence of enlarged nuclei evident by hematoxylin and eosin (H&E) staining (35) .
Conversely, the lack of in vivo effects of AZD-1152 in DLD-1 xenografts, predicted by [
18 F]FB-VAD-FMK PET, could possibly be attributed to poor drug exposure as little evidence of polyploidy was observed by H&E staining (Fig. 4D) .
[ 18 F]FB-VAD-FMK PET Reflects Response to Combination Therapy
Rational combination therapy for (Fig. 5C ). These observations were confirmed with semi-quantitative IHC analysis (Fig.   S4B ). In concert with elevated probe uptake, after four days of treatment a significant reduction in tumor size (p = 0.023) was observed in COLO-205 xenografts treated with combination therapy (Fig. 5D) 
Discussion
Irreversible caspase binding ligands are frequently utilized as tool compound inhibitors in vitro and in vivo (23, 24) . Among the known inhibitors, we sought to extend the utility of VAD-FMK-type peptides to PET imaging probe development. Mechanistically, VAD-FMK peptides irreversibly bind active caspase through condensation of the fluoromethyl ketone moiety with a cysteine thiol, Cys163 for caspase-3, within the active site, permanently inactivating the enzyme (26, 38) . As a molecular imaging probe, irreversible binding may confer certain advantages, such as enhanced retention in apoptotic versus healthy cells, due to slow dissociation kinetics. We believe this study is the first to report development and in vivo validation of a novel PET imaging probe derived from the VAD-FMK peptide sequence. In general, the VAD-FMK sequence is known to be quite versatile and has been previously functionalized with fluorophores (39) (40) (41) (42) and a radioisotope (33) for in vitro and certain preclinical applications. The probe developed here possesses all of the inherent advantages of a PET imaging agent, which include sensitivity, depth, and quantification (43, 44) . Furthermore, the FB derivative exhibits certain physical properties, such as improved water solubility which was a previously reported limitation of another reported labeled peptide IZ-VAD-FMK.
Inhibitor-caspase interactions have been reported (26) and provide reasonable structural templates for the design of inhibitor-based probes. The molecular modeling approaches employed in this study were confirmed by in vitro biochemical studies and suggested that FB-VAD-FMK would be accommodated in the caspase-3 active site without significant perturbation of physically plausible low-energy complex structures. We interpret our results, which identified a best-scoring docked pose for FB-VAD-FMK with the FBprosthesis pointed away from the active site and towards solvent, to suggest that further chemical However, other caspase-targeted PET agents reported in the literature and under clinical development are also known to exhibit modest uptake, including the promising isatin sulfonamide chemical class (46) (47) (48) and
Page | 17 well as that from previous reports (46) (47) (48) (49) (50) , it is not clear that improvements in the overall tumor uptake, which might result in greater signal-to-noise ratio, would result in a probe that better reflects the underlying determinants of apoptosis. Future head-to-head comparisons would be beneficial towards sorting this out.
Future studies should also evaluate the advantages and limitations inherent in the use of a pan-caspase targeting probe, where extrinsic and intrinsic apoptosis pathways are indistinguishable, compared with more selective compound classes.
Conclusion
These studies illuminate the VAD-FMK peptide as a promising scaffold for molecular imaging of caspase activity and response to molecularly targeted therapy using positron emission tomography. Among these peptides, [ 18 F]FB-VAD-FMK appears to be an attractive PET imaging probe for non-invasive quantification of apoptosis in tumors and may represent a potentially translatable biomarker of therapeutic efficacy in personalized medicine.
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